🇺🇸 Carboplatin, Etoposide, Ifosfamide in United States

71 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Neutropenia — 12 reports (16.9%)
  2. Cytokine Release Syndrome — 10 reports (14.08%)
  3. Off Label Use — 10 reports (14.08%)
  4. Product Use In Unapproved Indication — 7 reports (9.86%)
  5. Sepsis — 6 reports (8.45%)
  6. Thrombocytopenia — 6 reports (8.45%)
  7. Anaemia — 5 reports (7.04%)
  8. Drug Ineffective — 5 reports (7.04%)
  9. Febrile Neutropenia — 5 reports (7.04%)
  10. Ilium Fracture — 5 reports (7.04%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is Carboplatin, Etoposide, Ifosfamide approved in United States?

Carboplatin, Etoposide, Ifosfamide does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Carboplatin, Etoposide, Ifosfamide in United States?

University Hospital Muenster is the originator. The local marketing authorisation holder may differ — check the official source linked above.